Drug Trial Radar · NCT07694427
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Oct 2, 2026
Primary completion
Sep 6, 2029
Study completion Nov 8, 2032
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- ENGOT, GOG, APGOT
- First posted
- Jul 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to bevacizumab alone or active observation (AO). The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to bevacizumab alone OR AO and will help provide a better understanding of the main side effects of the drugs.
Conditions
- Ovarian Neoplasms
Interventions
Mocertatug rezetecanDrug
Mocertatug rezetecan will be administered
BevacizumabDrug
Bevacizumab will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to approximately 34 months
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
CABA, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina · Recruiting
GSK Investigational Site
Viedma, Argentina · Recruiting
GSK Investigational Site
Kogarah, New South Wales, Australia · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Niigata, Japan · Recruiting
GSK Investigational Site
Osaka, Japan · Recruiting
GSK Investigational Site
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
GSK Investigational Site
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.